Showing 3871-3880 of 5956 results for "".
- FDA Clears New World Medical's VIA360 Surgical Systemhttps://modernod.com/news/fda-clears-new-world-medicals-via360-surgical-system/2482667/New World Medical has received 510(k) clearance from the FDA for its VIA360 Surgical System for the delivery of controlled amounts of viscoelastic fluid during ophthalmic surgeries. The VIA360, which is also indicated to cut trabecular meshwork tissue during trabecul
- EssilorLuxottica Acquires Canadian Med-Tech Start-Up Cellviewhttps://modernod.com/news/essilorluxottica-acquires-canadian-med-tech-start-up-cellview/2482659/EssilorLuxottica has acquired Cellview Imaging, a Canadian start-up specializing in diagnostic via retinal imaging. Financial terms of the deal were not disclosed. Based in Toronto, Cellview designs and manufactures diagnostic imaging instruments. Currently distributed in North Ame
- DigitalOptometrics to Preview 'World’s First Autonomous Slitlamp' at Vision Expo East 2025https://modernod.com/news/digitaloptometrics-to-preview-worlds-first-autonomous-slitlamp-at-vision-expo-east-2025/2482655/DigitalOptometrics has announced the launch of what it is calling the world’s first and most advanced autonomous slitlamp with remote control capabilities at Vision Expo East (VEE) 2025 in Orlando. In collaboration with SlitLED, DigitalOptometrics will demonstrate t
- 4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Studyhttps://modernod.com/news/4dmt-presents-positive-52-week-results-from-phase-2b-cohort-of-prism-wet-amd-study/2482654/4D Molecular Therapeutics (4DMT) announced positive initial interim 52-week data from the phase 2b population extension cohort of the PRISM clinical trial evaluating 4D-150 in a broad wet age-related macular degeneration (AMD) patient population. Additional data were provided on the durabili
- Bausch + Lomb: No Immediate Plans to Go Privatehttps://modernod.com/news/bausch-lomb-no-immediate-plans-to-go-private/2482653/After exploring options to separate from Bausch Health, Bausch + Lomb announced Thursday it decided not to engage in a sale. “Taking Bausch + Lomb private with a third-party buyer was one of several options being explored to complete a full separation from Bausch Health Companies
- Pykus Therapeutics to Present Initial Clinical Data on Novel Retinal Sealanthttps://modernod.com/news/pykus-therapeutics-to-present-initial-clinical-data-on-novel-retinal-sealant/2482651/Pykus Therapeutics announced that it will present initial clinical data on its investigational retinal sealant, PYK-2101, to replace gas and oil during retinal detachment repair. The data will be presented at the Vail Vitrectomy 2025 Meeting on February 10, 2025. The presentat
- AI Optics Receives FDA Clearance for Handheld Retinal Imaging Systemhttps://modernod.com/news/ai-optics-receives-fda-clearance-for-handheld-retinal-imaging-system/2482650/AI Optics has received FDA 510(k) clearance for its Sentinel Camera, a handheld retinal imaging system designed to capture high-quality images of the eye. Al Optics said the device helps to address critical gaps in retinal disease screening through a
- EyePoint Announces Positive 6-Month Results for the Phase 2 VERONA Clinical Trial of Duravyu for DMEhttps://modernod.com/news/eyepoint-announces-positive-6-month-results-for-the-phase-2-verona-clinical-trial-of-duravyu-for-dme/2482649/EyePoint Pharmaceuticals announced positive 6-month results for the ongoing phase 2 VERONA clinical trial evaluating Duravyu (vorolanib intravitreal insert) for diabetic macular edema (DME). Duravyu is an investigational sustained delivery therapy delivering vorolanib, a selective tyros
- McKesson Acquires Controlling Interest in PRISM Vision Holdingshttps://modernod.com/news/mckesson-acquires-controlling-interest-in-prism-vision-holdings/2482645/McKesson Corp. has signed a definitive agreement to acquire an 80% controlling interest in Berkeley Heights, New Jersey-based PRISM Vision Holdings, a provider of general ophthalmology and retina management services, from private equity firm Quad-C. The transactio
- Rayner Completes Recruitment for RayOne Galaxy IDE Studyhttps://modernod.com/news/rayner-completes-recruitment-for-rayone-galaxy-ide-study/2482642/Rayner announced the closure of recruitment in the Investigational Device Exemption (IDE) study for the RayOne Galaxy IOL in the United States. Developed in collaboration with Brazilian ophthalmologist João Lyra, MD, PhD, RayOne Galaxy is the worl